DrugPatentWatch Database Preview
Email this page to a colleagueSee Plans and Pricing
« Back to Dashboard
MLN0128 is an investigational drug.
There have been 36 clinical trials for MLN0128. The most recent clinical trial was a Phase 1 trial, which was initiated on July 1st 2015.
The most common disease conditions in clinical trials are Neoplasms, Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.
There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-two international patents.
Recent Clinical Trials for MLN0128
|Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)||National Cancer Institute (NCI)||Phase 2|
|Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)||Southwest Oncology Group||Phase 2|
|Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer||National Cancer Institute (NCI)||Phase 1|
Top disease conditions for MLN0128
Top clinical trial sponsors for MLN0128
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN0128||Start Trial||Low, immune enhancing, dose mtor inhibitors and uses thereof||Novartis AG (Basel, CH)||Start Trial|
|MLN0128||Start Trial||Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases||ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)||Start Trial|
|MLN0128||Start Trial||Combination pharmaceutical compositions and uses thereof||INTELLIKINE LLC (La Jolla, CA)||Start Trial|
|MLN0128||Start Trial||Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor||Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|